Trade Summary

2 days ago, Metzger Michael A, serving as Chief Executive Officer at Syndax Pharmaceuticals Inc (SNDX), sold 32,375 shares at $24.24 per share, for a total transaction value of $784,776.48. Following this transaction, Metzger Michael A now holds 484,843 shares of SNDX.

This sale represents a 6.26% decrease in Metzger Michael A's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, July 8, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, July 9, 2026 at 4:54 PM ET, 1 day after the trade was made.

Syndax Pharmaceuticals Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.